Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD

Abstract

Inflammation modifies incidence and progression of Parkinson’s disease (PD). By using 30 inflammatory markers in CSF in 498 people with PD and 67 people with Dementia with Lewy Bodies (DLB) we show that: 1) levels of ICAM-1, Interleukin-8, MCP-1, MIP-1 beta, SCF and VEGF were associated with clinical scores and neurodegenerative CSF biomarkers (Aβ1–42, t-Tau, p181-Tau, NFL and α-synuclein). 2) PD patients with GBA mutations show similar levels of inflammatory markers compared to PD patients without GBA mutations, even when stratified by mutation severity. 3) PD patients who longitudinally developed cognitive impairment during the study had higher levels of TNF-alpha at baseline compared to patients without development of cognitive impairment. 4) Higher levels of VEGF and MIP-1 beta were associated with a longer duration until development of cognitive impairment. We conclude that the majority of inflammatory markers is limited in robustly predicting longitudinal trajectories of developing cognitive impairment.